Compare Organon & Co. Common Stock (OGN) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.09 (market cap $4.38B). The key difference: State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF for 42 Days on average.
| OGN | SJNK | |
|---|---|---|
Market Cap | $3.61B | $4.38B |
Volume | 1,808,049 | 5,307,890 |
Sector | Health | Fixed Income |
52-Week High | $13.81 | $25.57 |
52-Week Low | $5.70 | $24.10 |
Typical Hold Time | 0 Days | 42 Days |
Enterprise Value | $11.03B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
SJNK trades at $24.19, showing minimal daily movement with a slight decline of 0.21%. The technical outlook appears bearish based on moving averages, though oscillators suggest neutral conditions. Recent corporate actions include consistent dividend payments, with three distributions scheduled for late 2026 ranging from $0.14 to $0.15 per share. Institutional activity shows mixed sentiment with both position reductions and maintained stakes among major holders.
The ETF faces headwinds from bearish technical indicators while maintaining dividend distributions. Key risks include interest rate sensitivity and institutional selling pressure. The neutral oscillator reading suggests potential for stabilization, but the overall technical picture warrants caution for near-term positioning in this high-yield bond ETF.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
